Published in Oncogene on October 17, 2011
Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther (2013) 1.41
Oncolytic viruses as anticancer vaccines. Front Oncol (2014) 1.13
DangER: protein ovERload. Targeting protein degradation to treat myeloma. Haematologica (2012) 1.06
Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects. Clin Cancer Res (2014) 1.02
Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget (2015) 0.98
Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer. Cell Death Dis (2013) 0.95
A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clin Cancer Res (2014) 0.91
Clinical use of proteasome inhibitors in the treatment of multiple myeloma. Pharmaceuticals (Basel) (2014) 0.91
A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report. Pediatr Blood Cancer (2015) 0.81
Reovirus as a successful ex vivo purging modality for multiple myeloma. Bone Marrow Transplant (2013) 0.81
ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma. PLoS One (2012) 0.80
Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells. Front Oncol (2014) 0.80
BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress. Mol Ther (2015) 0.80
Activity levels of cathepsins B and L in tumor cells are a biomarker for efficacy of reovirus-mediated tumor cell killing. Cancer Gene Ther (2015) 0.79
Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus. Viruses (2015) 0.78
Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. Oncotarget (2015) 0.77
The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer. BMC Cancer (2015) 0.77
Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. Mol Cancer Ther (2016) 0.75
A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry (1995) 3.65
Lymph node recovery from colorectal resection specimens removed for adenocarcinoma. Trends over time and a recommendation for a minimum number of lymph nodes to be recovered. Am J Clin Pathol (1996) 3.52
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50
Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol (2001) 3.38
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia (2003) 2.60
Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of lymphoma. Thorax (2007) 2.20
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol (2001) 1.96
Cusum plotting of temperature charts for assessing antimicrobial treatment in neutropenic patients. BMJ (1989) 1.95
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer (1999) 1.90
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther (2008) 1.88
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia (2013) 1.77
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia (2006) 1.67
The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica (1999) 1.54
Targeting HSP90 for cancer therapy. Br J Cancer (2009) 1.44
Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma. Br J Cancer (2011) 1.44
Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med (1996) 1.43
Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther (2008) 1.41
Plasma as a source of mRNA for determining IgV(H) mutation status in patients with chronic lymphocytic leukaemia. Br J Haematol (2006) 1.40
Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood (1999) 1.40
Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther (2009) 1.40
Evidence of genetic resistance of cattle to infection with Mycobacterium bovis. J Dairy Sci (2010) 1.32
Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev (2008) 1.30
Universal vs. risk factor-based screening for gestational diabetes mellitus: detection rates, gestation at diagnosis and outcome. Diabet Med (2000) 1.27
Reciprocal control of osteoblast/chondroblast and osteoblast/adipocyte differentiation of multipotential clonal human marrow stromal F/STRO-1(+) cells. J Cell Biochem (2001) 1.24
Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest (1996) 1.22
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia (2008) 1.21
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia (2013) 1.20
Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. Leukemia (2004) 1.20
Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia (2005) 1.18
Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies. Clin Lab Haematol (2006) 1.14
Neuregulin 1 (8p12) and childhood-onset schizophrenia: susceptibility haplotypes for diagnosis and brain developmental trajectories. Mol Psychiatry (2006) 1.12
Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene Ther (2012) 1.08
Enhancement of seed oil content by expression of glycerol-3-phosphate acyltransferase genes. Biochem Soc Trans (2000) 1.07
Regulation of osteogenic differentiation of human bone marrow stromal cells: interaction between transforming growth factor-beta and 1,25(OH)(2) vitamin D(3) In vitro. Calcif Tissue Int (1999) 1.06
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia (2003) 1.05
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer (1999) 1.03
A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia (2011) 1.02
Effects of growth factors and interleukin-1 alpha on proteoglycan and type II collagen turnover in bovine nasal and articular chondrocyte pellet cultures. Endocrinology (1996) 1.01
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia (2011) 1.00
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer (2001) 1.00
The role of Hispanic race/ethnicity and poverty in breast cancer survival. P R Health Sci J (1995) 0.99
Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood (2001) 0.98
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia (2006) 0.96
Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood (1999) 0.95
Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer. Cell Death Dis (2013) 0.95
Granulocytic sarcoma of the pancreas: a report of two cases and literature review. Clin Lab Haematol (1999) 0.95
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia (2007) 0.94
A prospective study to identify high-yield criteria associated with acute intracranial computed tomography findings in head-injured patients. Am J Emerg Med (1993) 0.94
Granulocytic sarcoma of the small intestine preceding acute myelomonocytic leukemia with abnormal eosinophils and inv(16). Cancer Genet Cytogenet (1988) 0.94
Utility of predictive equations for estimating the prevalence and incidence of primary open angle glaucoma in the UK. Br J Ophthalmol (2000) 0.93
The cell biology of bone growth. Eur J Clin Nutr (1994) 0.93
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol (1999) 0.92
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia (2006) 0.92
Ventilation and gas exchange during sleep in patients with interstitial lung disease. Thorax (1986) 0.91
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia (2001) 0.90
Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. Int J Cancer (2013) 0.90
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol (1999) 0.89
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer (2001) 0.89
Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo. Br J Haematol (1994) 0.88
Myelodysplasia presenting as granulocytic sarcoma of mediastinum causing superior vena cava syndrome. Leuk Lymphoma (2000) 0.88
Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts. Br J Haematol (2000) 0.88
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leuk Lymphoma (2001) 0.87
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol (2000) 0.87
Genetic parameters for production, health, fertility and longevity traits in dairy cows. Animal (2012) 0.87
Sindbis virus infection in Australia. Med J Aust (1969) 0.86
Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense. Hypertension (1997) 0.86
Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies. Leukemia (2012) 0.86
Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am (1998) 0.86
Organochlorine chemicals in tree swallows nesting in pool 15 of the Upper Mississippi River. Bull Environ Contam Toxicol (2000) 0.86
Recovery: what mental health nurses and service users say about the concept of recovery. J Psychiatr Ment Health Nurs (2011) 0.85
Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. Leukemia (2005) 0.85
ELR510444, a novel microtubule disruptor with multiple mechanisms of action. J Pharmacol Exp Ther (2010) 0.84
Neutrophils from AIDS patients treated with granulocyte colony-stimulating factor demonstrate enhanced killing of Mycobacterium avium. J Infect Dis (1998) 0.84
Segmental uniparental isodisomy on 5q32-qter in a patient with childhood-onset schizophrenia. J Med Genet (2006) 0.83
Effects of nasal airflow on breathing during sleep in normal humans. Am Rev Respir Dis (1993) 0.83
Upper airway obstruction during sleep in normal subjects after selective topical oropharyngeal anesthesia. Am Rev Respir Dis (1987) 0.83
Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia. Leukemia (2012) 0.83
Breeding and Genetics Symposium: really big data: processing and analysis of very large data sets. J Anim Sci (2011) 0.82
Cystic fibrosis in adolescents and adults. Ir Med J (1992) 0.82
Radiation to control transgene expression in tumors. Cancer Biol Ther (2007) 0.82
Role of leukotrienes in antimicrobial defense of the lung. J Lab Clin Med (1998) 0.82
Mid-infrared prediction of bovine milk fatty acids across multiple breeds, production systems, and countries. J Dairy Sci (2011) 0.82
Eye care utilisation patterns in a rural county in Ireland: implications for service delivery. Br J Ophthalmol (1997) 0.81
Burkitt translocation (8;22)(q24;q11) in a patient with multiple myeloma. Cancer Genet Cytogenet (1995) 0.81
The EORTC clinical research coordinators group. European Organisation for Research and Treatment of Cancer. Eur J Cancer (2002) 0.81
Therapeutic choices in younger patients with chronic myelogenous leukemia. Cancer (2000) 0.80
A chest radiograph scoring system in adult cystic fibrosis: correlation with pulmonary function. Clin Radiol (1991) 0.80
Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol (2008) 0.80
Cells cultured from the growing tip of red deer antler express alkaline phosphatase and proliferate in response to insulin-like growth factor-I. J Endocrinol (1994) 0.80